Compare BOSC & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | PMN |
|---|---|---|
| Founded | 1990 | 2004 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 23.5M |
| IPO Year | 1996 | N/A |
| Metric | BOSC | PMN |
|---|---|---|
| Price | $4.66 | $15.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 55.3K | ★ 445.5K |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $48,333,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.07 | ★ N/A |
| Revenue Growth | ★ 19.49 | N/A |
| 52 Week Low | $3.30 | $6.27 |
| 52 Week High | $6.72 | $39.75 |
| Indicator | BOSC | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 70.50 |
| Support Level | $4.55 | $8.96 |
| Resistance Level | $5.35 | $17.40 |
| Average True Range (ATR) | 0.24 | 1.87 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 7.50 | 56.84 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.